Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease

To verify the in vivo efficacy of sulfoxide and sulfone fexinidazole metabolites following oral administration in a model of Chagas disease

Abstract

This study was designed to verify the in vivo efficacy of sulfoxide and sulfone fexinidazole metabolites following oral administration in a murine model of Chagas disease.

This study was funded by the Drugs for Neglected Diseases initiative (DNDi)

Citation

Bahia MT, Nascimento AF, Mazzeti AL, Marques LF, Gonçalves KR, Mota LW, Diniz LD, Caldas IS, Talvani A, Shackleford DM, Koltun M, Saunders J, White KL, Scandale I, Charman SA, Chatelain E. (2014) Antitrypanosomal Activity of Fexinidazole Metabolites, Potential New Drug Candidates for Chagas Disease. Antimicrobial Agents and Chemotheraphy. August 2014 vol. 58 no. 8 4362-4370 doi: 10.1128/AAC.02754-13

Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease

Updates to this page

Published 1 May 2014